BIOANALYTICAL SYSTEMS INC BASI Cash Flow

Bioanalytical systems inc (BASI)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10
Operating activities:
Net loss
-588	-1,426	290	-426	-569	-85	-200	-75	55	26	229	221	417	17	-2,037	-433	-254	-506	-711	1,478	150	182	-404	215	-219	-662	252	576	-311	256	-2,696	-246	-1,828	-1,547	1,091	418	483	310
Adjustments to reconcile net loss to net cash provided by operating activities, net of acquisition:
Depreciation and amortization
941	732	680	713	611	713	715	378	378	404	377	443	464	396	525	343	346	342	368	339	353	377	402	396	397	402	410	405	435	473	554	579	594	551	560	525	519	530
Amortization finance lease
43	32	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Employee stock compensation expense
123	81	82	72	99	25	32	34	34	34	6	6	-3	10	11	5	14	15	12	19	19	29	19	20	-2	47	38	52	61	74	-36	46	26	47	30	48	21	54
Decrease in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-21	-79	-89	-134	-34	-199	-120	-177	-66	200	961	-308	-318	142	-117	385	-458	-56	56	-	-	-	-
Provision for doubtful accounts, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-2	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on interest rate swaps
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	10	21
Gain on disposal of property and equipment
-	-	-4	0	0	3	-1	0	2	-1	-4	3	1	5	-2	0	-1	-11	12	-3	-2	0	-	-	-	-	0	-6	21	-2	-429	-19	-1	-2	0	0	10	-1
Unrealized foreign currency gains
13	-18	12	11	-10	146	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for doubtful accounts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	103	0	20	-39	-	-	-	-	-	-	-	-	-	-	-	-	-	0	43	3	5	1	7	3
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6	0	0	-8
Changes in operating assets and liabilities:
Accounts receivable
860	1,013	1,610	1,743	250	-516	66	520	422	-419	685	-741	374	623	-1,128	-205	1,168	-1,474	473	297	-41	355	-549	81	497	-939	967	-266	711	-1,387	-508	101	75	-570	-39	-40	443	-128
Inventories
170	-61	-24	16	-69	-10	218	-36	69	18	-151	-55	-248	-86	-23	60	-18	-32	-95	-111	10	98	29	28	56	72	-100	-173	-51	47	-89	-109	-8	226	-11	81	-52	-55
Income tax accruals
5	97	-33	1	29	0	10	-31	6	-67	-3	7	2	1	1	-17	21	-22	-10	20	3	-3	15	-17	6	-14	-	-	-	-	-	-	-	-	-	-	-	-
Income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-18	3	0	-	0	0	46	-	-	-	-
Prepaid expenses and other assets
-51	774	-68	-46	0	227	388	-238	-246	173	215	-160	137	-178	41	374	-37	-351	243	97	-252	9	-296	153	343	145	45	-28	66	-74	-134	-129	-41	-110	-96	52	112	-85
Accounts payable
-1,056	479	355	809	387	-532	945	249	113	-327	396	-347	-1,043	81	132	649	840	-499	485	-104	-350	228	-697	14	165	-345	-250	212	-313	82	1,498	-9	-25	911	117	-871	648	-376
Accrued expenses
-1,088	666	130	1,048	-646	317	240	-218	-97	178	11	-96	-19	217	265	-480	322	-728	643	-233	-44	-498	510	-325	119	-151	444	-175	135	-782	30	-97	233	139	10	-14	78	-160
Customer advances
1,290	2,501	244	329	264	319	204	1,279	-156	283	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Customer advances
-	-	-	-	-	-	-	-	-	-	-285	-498	-2	651	-293	327	356	-690	405	-473	386	106	-332	235	196	76	438	-298	348	-685	-619	-47	87	20	-860	-101	-185	136
Net cash provided by operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	144	474	-348	929	735	601	-161	469	210	-31	1,036	-	915	-214	717	-	-	-	-	-	-	-	-
Net cash provided by operating activities
-1,241	1,454	210	656	4	907	1,277	1,368	82	760	-14	689	-448	1,009	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	237	-76	-951	590	-610	-87	1,048	737
Investing activities:
Capital expenditures
0	4,000	-	-	-	684	391	493	258	175	134	55	53	105	419	205	466	166	801	435	109	122	147	193	99	51	-7	3	2	10	110	163	105	712	539	283	41	311
Cash paid in acquisition
1,186	2,165	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of equipment
-	-	-	-	-	-	-	-	-	-	0	2	1	5	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-205	-466	-166	-768	-435	-109	-122	-147	-193	-99	-51	-	-3	18	-10	-	-	-	-	-	-	-	-
Net cash used in investing activities
-1,186	-6,165	-2,348	-3,583	-1,534	-684	-7,150	-493	-256	-175	-134	-53	-52	-100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	120	-163	-105	-712	-539	-283	-41	-311
Financing activities:
Payments on finance lease liability
42	37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of long-term debt
353	250	-180	638	227	224	164	56	56	55	55	3,339	131	196	197	196	197	196	197	196	197	196	197	5,018	252	49	149	146	127	166	166	191	190	188	184	182	686	704
Payments of debt issuance costs
1	110	2	70	11	11	-	-	0	0	0	169	28	17	27	41	0	0	-	-	-	-	73	61	0	60	-	60	0	15	-	-	-	-	-	-	-	-
Payments on revolving line of credit
12,180	10,531	9,169	7,988	5,613	5,892	0	2,460	2,274	2,811	350	4,343	6,062	761	3,472	2,609	2,750	2,473	2,171	2,037	2,435	1,097	999	0	1,924	7,619	5,044	5,752	4,900	6,118	6,457	6,558	7,068	7,612	7,624	8,138	7,403	7,752
Borrowings on revolving line of credit
14,069	10,194	9,660	8,151	6,022	5,892	0	2,460	2,274	2,811	-	-	-	-	3,279	3,032	3,054	3,211	2,257	2,037	1,955	1,375	1,201	0	1,756	6,372	6,127	5,271	4,751	5,636	6,638	6,721	6,915	7,519	7,470	8,524	7,057	8,017
Borrowings on construction loan
-94	1,183	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Borrowings on capex line of credit
601	728	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of capital lease obligations
-	-	-	6	38	38	-	33	32	31	31	32	30	34	60	86	64	67	65	63	76	75	73	72	65	66	65	63	102	100	168	176	160	151	123	899	155	164
Borrowings on long-term loan
94	3,439	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-1	4	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used) provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100	42	479	-208	-259	-753	7	-139	372	-324	-1,422	-	-750	-378	-763	-	-	-	-	-	-	-	-
Net cash provided by financing activities
2,114	4,616	2,238	2,913	1,327	-273	5,188	-89	-87	-86	-337	-136	632	-1,008	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-25	-204	-503	-432	-494	3,944	-1,187	-603
Net decrease in cash and cash equivalents
-313	-95	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-61	50	42	62	-32	-8	-26	-61	11	44	5	-20	-1	0	3	-26	-14	14	-7
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-50	-	-	-261	499	-485	500	132	-99	-106	39	50	-35	-78	-20	-211	-234	245	357	-462	-463	991	173	-530	-51	312	-444	-1,559	-551	-1,669	3,560	-166	-184
Supplemental disclosure of cash flow information:
Cash paid for interest
224	270	198	143	109	116	94	45	46	48	50	41	82	57	116	77	61	58	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preclinical Research Services acquisition:
Assets acquired
0	6,435	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities assumed
0	1,302	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common shares issued
0	1,133	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	8	18	18	21	20	20	20	-	-	-	-	-	-	-	-
Cash paid
0	4,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Smithers Avanza Toxicology Services LLC acquisition
Net loss
-	31	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-